Biotechnology - Asia-Pacific, Rare diseases


Current filters:

Asia-PacificRare diseases

Popular Filters

New Zealand to widen access for type 1 and type 3 Gaucher disease drug


New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval of a proposal to widen…

Asia-PacificBiotechnologyCerezymeGenzymePharmaceuticalRare diseasesRegulationSanofi

Alnylam gets upfront $22.5 million in RNAi link with Genzyme


French drug major Sanofi's (Euronext: SAN) US biotech subsidiary Genzyme has entered into an exclusive…

Alnylam PharmaceuticalsAsia-PacificBiotechnologyGenzymeLicensingPharmaceuticalRare diseasesSanofi

EMA increases interaction with Japanese regulators


The European Medicines Agency has increased its level of interaction and cooperation with medicines regulatory…

Asia-PacificBiotechnologyEuropePharmaceuticalRare diseasesRegulation

Actelion drops setipiprant, gets miglustat approval in Japan


Switzerland-based Actelion Ltd (SIX: ATLN) announced says that it will re-direct its development efforts…

ActelionAsia-PacificBiotechnologyBrazavesInflammatory diseasesMiglustatRare diseasesRegulationResearchsetipiprantZavesca

Pharming in deal with Hyupjin for Ruconest in South Korea


Dutch biotech firm Pharming Group (NYSE Euronext: PHARM) has entered into an agreement with Seoul-based…

Asia-PacificBiotechnologyHyupjin CorpLicensingPharmingRare diseasesRhucinRuconest

Back to top